Analysts' ratings for Vertex Pharmaceuticals VRTX over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings, showcasing the ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

{2}\). The line crosses the 𝑦-axis at 3, so the 𝑦-intercept is 3. Back to top Equation of a line from a graph – interactive activity Working with the general equation of a straight line ...

Vertex has become the latest big pharma company to acknowledge the potential of machine learning in drug development, announcing a three-year collaboration with the UK’s Genomics plc to use ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

A memorandum opinion by Chief Judge James E. Boasberg of the US District Court for the District of Columbia upheld a US Department of Health and Human Services advisory opinion that found that Vertex ...

The AICPA endorsed four of the six bills, all of which passed with bipartisan support and were forwarded to the Senate.